Zhelezodefitsit v kardiologii - novyy podkhod k staroy probleme?


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In recent years, the number of scientific papers on the diagnosis and treatment of iron deficiency regardless of the presence of anemia in patients with cardiovascular diseases is increased. In cardiology practice this approach came from the field of nephrology, since many diagnostic and therapeutic approaches to the treatment of anemia and/or iron deficiency were evaluated in patients with chronic renal failure and often concomitant chronic heart failure. Results of recent studies highlighted in this review led to the question of the recognition of iron deficiency as independent risk factor for worsening prognosis of patients with cardiovascular diseases, and, therefore, as therapeutic target not related to anemia.

全文:

受限制的访问

作者简介

F. Kopylov

参考

  1. Boyd C.M., Leff B., Wolff J.L., et al. Informing clinical practice guideline development and implementation: prevalence of coexisting conditions among adults with coronary heart disease. J Am Geriatr Soc 2011;59(5): 797-805.
  2. Jankowska E.A., Rozentryt P., Witkowska A,. et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31(15):1872-80.
  3. Sabatine M.S., Morrow D.A., Giugliano R.P., et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005;111(16):2042-49.
  4. Anand I., McMurray J.J., Whitmore J., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004;110(2):149-54.
  5. O'Meara E., Clayton T., McEntegart M.B., et al. CHARM Committees and Investigators. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006;113(7):986-94.
  6. Pereira A.A., Sarnak M.J. Anemia as a risk factor for cardiovascular disease Kidney Int 2003;64(Suppl. 87):32-9.
  7. Vlagopoulos P.T., Tighiouart H., Weiner D.E., et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005;16(11):3403-10.
  8. Sullivan J.L. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-94. a. Weissert S., Flint J., Aggarwal S., et al. Iron Deficiency as the Most Ominous Substrate for Anemia in Patients Undergoing Coronary Artery Bypass Surgery Circulation 2011;124: Abstract17396.
  9. Cook J.D., Lipschitz D.A., Miles L.E., et al: Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr 1974;27:681-87.
  10. Burt M.J., Halliday J.W., Powell L.W. Iron and coronary heart disease. BMJ 1993; 307:575-76.
  11. Cooper C.E. Nitric oxide and iron proteins. Biochim Biophys Acta 1999;1411:290-309.
  12. Ponka P. Cellular iron metabolism. Kidney Int 1999; 55(69):S2-S11.
  13. Cairo G., Bernuzzi F., Recalcati S. Apreciousmetal: iron, an essential nutrient for all cells. Genes and Nutrition 2006;1:25-40.
  14. Anderson G.J., Vulpe C.D. Mammalian iron transport. Cell and Mol Life Sciences 2009;66(20):3241-61.
  15. Dallman P.R. Iron deficiency: does it matter? J Intern Med 1989;226:367-72.
  16. Haas J.D., Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001;131:S676-S88.
  17. Anker S.D., Colet J.C., Filippatos G., et al. FAIR-HF committees and investigators. Rationale and design of Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084-91.
  18. Beard J.L. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131(2 Suppl. 2):S568-S79.
  19. Weiss G., Goodnough L.T. Anemia of Chronic Disease. New Eng J Med 2005;352(10): 1011-23.
  20. Mastromarino V., Volpe M., Musumeci M.B., et al. Erythropoietin and the heart: facts and perspectives. Clin Sci (Lond) 2011; 120(2):51-63.
  21. Silverberg D.S., Wexler D., Blum M., Iaina A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clinical Nephrology 2003;60(1):93-102.
  22. Silverberg D.S., Wexler D., Iaina A., Schwartz D. Correction of iron deficiency in the cardiorenal syndrome. Int J Nephrol 2011;2011:365301.
  23. http://www. who.int/vmnis/indicators/serum_ ferritin_ru.pdf.
  24. Kansagara D., Dyer E., Englander H., Freeman M., Kagen D. Treatment of Anemia in Patients with Heart Disease: A Systematic Review [Internet]. Washington (DC): Department of Veterans Affairs (US);2011 Oct.
  25. http://www.ncbi.nlm.nih.gov/books/ диагностике и лечению острой и хронической сердечной недостаточности 2012 г. дано указание на выявление и лечение железодефицитных состояний у больных ХСН [33]. NBK83423/pdf/TOC.pdf.
  26. Anker S.D., Comin Colet J., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine 2009;361(25):2436-48.
  27. Toblli J.E., Lombrana A., Duarte P., Di Gennaro F. Intravenous iron reduces NTpro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. Journal of the American College of Cardiology 2007;50(17):1657-65.
  28. Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. Journal of the American College of Cardiology 2008;51(2):103-12.
  29. Van Wyck D.B., Roppolo M., Martinez C.O., et al, for the United States Iron Sucrose (Venofer) Clinical Trials Group: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005;68:2846-56.
  30. Rozen-Zvi B., Gafter-Gvili A., Paul M., et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008;52:897-906.
  31. Palazzuoli A., Silverberg D. S., Iovine F. et al. Effects of /3-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. American Heart Journal 2007;154(4): 645e9-5e15.
  32. Krum H., Jelinek M.V., Stewart S., Sindone A., Atherton J.J. National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust 2011;194(8):405-9.
  33. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;33(14):1787-847.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2012
##common.cookie##